INT151289

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.51
First Reported 2007
Last Reported 2008
Negated 0
Speculated 0
Reported most in Body
Documents 4
Total Number 5
Disease Relevance 2.17
Pain Relevance 0.12

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

Golgi apparatus (Mal) endoplasmic reticulum (Mal) plasma membrane (Mal)
Anatomy Link Frequency
dermis 1
epidermis 1
ducts 1
Mal (Mus musculus)
Pain Link Frequency Relevance Heat
medulla 1 86.04 High High
Angina 1 74.32 Quite High
rheumatoid arthritis 2 50.00 Quite Low
spinal inflammation 2 50.00 Quite Low
Inflammatory marker 1 50.00 Quite Low
Pain 29 5.00 Very Low Very Low Very Low
cryotherapy 6 5.00 Very Low Very Low Very Low
analgesia 2 5.00 Very Low Very Low Very Low
Pain score 2 5.00 Very Low Very Low Very Low
antagonist 2 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Sclerosis 1 94.80 High High
Diffuse Large B-cell Lymphoma 2 89.00 High High
Lymphatic System Cancer 4 88.72 High High
Cancer 20 85.68 High High
Hodgkin's Disease 1 84.56 Quite High
Skin Cancer 106 78.40 Quite High
Cough 1 74.88 Quite High
Angina 1 74.32 Quite High
Dyspnea 1 73.36 Quite High
Superior Vena Cava Syndrome 1 72.32 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
There was a negative correlation between MPV values and BASDAI scores in AS patients after two months of treatment (r=-0.507; p=0.004).
Gene_expression (values) of MPV
1) Confidence 0.51 Published 2008 Journal Joint Bone Spine Section Body Doc Link 18403245 Disease Relevance 0.20 Pain Relevance 0
When ALA or MAL is applied topically, sufficient amounts of drug have been found to be present in both epidermis and dermis, although the dermal cells do not develop significant PpIX levels to become photosensitized (Divaris et al 1990).
Gene_expression (applied) of MAL in dermis
2) Confidence 0.40 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2503644 Disease Relevance 0.37 Pain Relevance 0
When ALA or MAL is applied topically, sufficient amounts of drug have been found to be present in both epidermis and dermis, although the dermal cells do not develop significant PpIX levels to become photosensitized (Divaris et al 1990).
Gene_expression (applied) of MAL in epidermis
3) Confidence 0.14 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2503644 Disease Relevance 0.37 Pain Relevance 0
cortical and medullary collecting ducts, and the MAL (see Figure 4(a) and Table 3).
Gene_expression (ducts) of MAL in ducts
4) Confidence 0.05 Published 2007 Journal Mediators of Inflammation Section Body Doc Link PMC1906712 Disease Relevance 0 Pain Relevance 0
Its main molecular characteristics include: gains in 9p segments, p53 mutations, BCL-2 and MAL gene over-expression, somatic mutations of IgVH genes, BCL-6, PIM-1, PAX-5, RhoH/TTF, and c-MYC, and constitutional NF-kappaB activation.
Gene_expression (over-expression) of MAL gene
5) Confidence 0.00 Published 2008 Journal Crit. Rev. Oncol. Hematol. Section Abstract Doc Link 18774728 Disease Relevance 1.22 Pain Relevance 0.12

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox